ESPR Overview

Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and delivering cardiometabolic and rare/orphan disease therapies. It markets two oral, once-daily, non-statin therapies for patients struggling to maintain their low-density lipoprotein cholesterol (LDL-C) levels who are at risk of cardiovascular disease and nasal spray, loop diuretic for the treatment of edema associated with congestive heart failure, and hepatic and renal disease. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. NEXLETOL is a first-in-class ACLY inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating LDL receptors. NEXLIZET contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and cholesterol absorption in the intestine. Its Enbumyst is the FDA-approved nasal spray loop diuretic.

Wall Street analysts forecast ESPR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ESPR is7.94 USD with a low forecast of 1.72 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Esperion Therapeutics Inc revenue for the last quarter amounts to 80.10M USD, increased 23.25

Esperion Therapeutics Inc. EPS for the last quarter amounts to -0.10 USD, decreased -52.38

Esperion Therapeutics Inc (ESPR) has 294 emplpoyees as of May 25 2026.

Today ESPR has the market capitalization of 805.76M USD.